Israel Englander Mi Nk Therapeutics, Inc. Transaction History

Millennium Management LLC

  • $199 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$0.87 - $1.56 $6,069 - $10,882
-6,976 Reduced 34.71%
13,121 $12,000
Q1 2024

May 15, 2024
BUY
$0.84 - $1.12 $16,881 - $22,508
20,097 New
20,097 $18,000
Q4 2022

Feb 14, 2023
BUY
$1.89 - $3.16 $20,557 - $34,371
10,877 New
10,877 $28,000

Others Institutions Holding INKT

# of Institutions
29
Shares Held
848K
Call Options Held
0
Put Options Held
0
View Full List

About MiNK Therapeutics, Inc.

INKT Quotes by TradingView
  • Ticker INKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,775,100
  • Market Cap $24.3M
  • Description
  • MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...
More about INKT
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email